Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMARCA2 | P51531 | 3/20 | 0.66 |
| ▸ | PBRM1 | Q86U86 | 3/20 | 0.66 |
| ▸ | SMARCA4 | P51532 | 2/20 | 0.66 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.45 |
| ▸ | GSK3A | P49840 | 1/20 | 0.45 |
| ▸ | GSK3B | P49841 | 1/20 | 0.45 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.42 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.42 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23205340 | 0.81 | RAB9A (0.52) | SMARCA2PBRM1SMARCA4MEN1KMT2A | |
| SCHEMBL10746633 | 0.81 | USP7 (0.44) | SMARCA2PBRM1SMARCA4MEN1KMT2A | |
| SCHEMBL19554988 | 0.81 | RAB9A (0.43) | SMARCA2PBRM1SMARCA4MEN1KMT2A | |
| SCHEMBL19554650 | 0.80 | CYP2A6 (0.50) | SMARCA2PBRM1SMARCA4MEN1KDM4E | |
| SCHEMBL19555195 | 0.80 | KDM4E (0.49) | SMARCA2PBRM1SMARCA4MEN1KMT2A | |
| SCHEMBL29912639 | 0.79 | SMARCA2 (1.00) | SMARCA2PBRM1SMARCA4ALDH1A1MAPT | |
| SCHEMBL10634913 | 0.79 | SMARCA2 (1.00) | SMARCA2PBRM1SMARCA4ALDH1A1MAPT | |
| SCHEMBL19555117 | 0.78 | MAOB (0.51) | KMT2AKDM4EALDH1A1MAPTRAB9A | |
| SCHEMBL2494812 | 0.78 | RAB9A (0.58) | SMARCA2PBRM1SMARCA4MEN1KMT2A | |
| SCHEMBL11119651 | 0.77 | PKM (0.50) | SMARCA2PBRM1SMARCA4MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9663493-B2 | Pyridazine compounds, compositions and methods | NORTHWESTERN UNIVERSITY (US) | 2017-05-30 | — | — | US | disclosed |
| US-9663493-B2 | Pyridazine compounds, compositions and methods | NORTHWESTERN UNIVERSITY (US) | 2017-05-30 | — | — | US | disclosed |
| US-9527819-B2 | Pyridazine compounds, compositions and methods | NORTHWESTERN UNIVERSITY | 2016-12-27 | — | — | US | disclosed |
| US-9527819-B2 | Pyridazine compounds, compositions and methods | NORTHWESTERN UNIVERSITY | 2016-12-27 | — | — | US | disclosed |
| US-20160326139-A1 | PYRIDAZINE COMPOUNDS, COMPOSITIONS AND METHODS | NORTHWESTERN UNIVERSITY (US) | 2016-11-10 | — | — | US | disclosed |
| US-20160326139-A1 | PYRIDAZINE COMPOUNDS, COMPOSITIONS AND METHODS | NORTHWESTERN UNIVERSITY (US) | 2016-11-10 | — | — | US | disclosed |
| US-9242961-B2 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2016-01-26 | — | — | US | disclosed |
| US-20150175555-A1 | PYRIDAZINE COMPOUNDS, COMPOSITIONS AND METHODS | NORTHWESTERN UNIVERSITY (US) | 2015-06-25 | — | — | US | disclosed |
| US-20150175555-A1 | PYRIDAZINE COMPOUNDS, COMPOSITIONS AND METHODS | NORTHWESTERN UNIVERSITY (US) | 2015-06-25 | — | — | US | disclosed |
| EP-2592075-B1 | PYRIDAZINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISEASES | UNIV NORTHWESTERN (US) | 2015-04-29 | — | — | EP | disclosed |
| WO-2008109437-A2 | COMPOSITIONS AND TREATMENTS FOR SEIZURE-RELATED DISORDERS | NORTHWESTERN UNIVERSITY (US) | 2008-09-12 | — | — | WO | disclosed |
| WO-2007130383-A2 | COMPOSITIONS AND TREATMENTS USING PYRIDAZINE COMPOUNDS AND SECRETASES | NORTHWESTERN UNIVERSITY (US) | 2007-11-15 | — | — | WO | disclosed |
| US-20070185111-A1 | Aurora kinase modulators and method of use | AMGEN INC. | 2007-08-09 | — | — | US | disclosed |
| US-4910199-A | Substituted with a phenyl ring | SANOFI (FR) | 1990-03-20 | — | — | US | disclosed |
| US-4873243-A | ANTIDEPRESSANTS OR PYCHOTONICS | SANOFI (FR) | 1989-10-10 | — | — | US | disclosed |
| US-4721711-A | Pyridazine derivatives active on the central nervous system, and medicaments in which they are present | SANOFI | 1988-01-26 | — | — | US | disclosed |
| US-4677106-A | ANTIDEPRESSANTS | SANOFI (FR) | 1987-06-30 | — | — | US | disclosed |
| US-4623376-A | PRE- AND POSTEMERGENCE | AMERICAN CYANAMID COMPANY (US) | 1986-11-18 | — | — | US | disclosed |
| US-4576946-A | ANTIDEPRESSANT | SANOFI (FR) | 1986-03-18 | — | — | US | disclosed |
| US-4514397-A | Derivatives of 4-methyl 6-phenyl pyridazine active on the central nervous system | SANOFI (FR) | 1985-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185111-A1 | Aurora kinase modulators and method of use | AURKC, AURKA, CDK1 | SMARCA2 2149/4885PBRM1 1944/4885SMARCA4 2815/4885 |
| US-20160326139-A1 | PYRIDAZINE COMPOUNDS, COMPOSITIONS AND METHODS | PSEN1, PSEN2, APP | SMARCA2 3406/4885PBRM1 1839/4885SMARCA4 3134/4885 |
| US-20150175555-A1 | PYRIDAZINE COMPOUNDS, COMPOSITIONS AND METHODS | PSEN1, PSEN2, APP | SMARCA2 3406/4885PBRM1 1839/4885SMARCA4 3134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.